{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-044969","form_type":"8-K/A","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.262419+00:00","generated_at":"2026-05-15T05:29:09.133549+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iBio corrects Series G warrant expiration to May 20, 2026; clinical trial for IBIO-600 cleared in Australia","bullets":["Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).","Outstanding Series G warrants to purchase ~11.07M shares; 36.14M shares of common stock outstanding as of April 17, 2026.","Received CTN acknowledgement from Australia's TGA and ethics approval for Phase 1 trial of IBIO-600; first dosing expected Q2 2026.","Pre-funded warrants for 13.79M shares issued upon exercise of Series G warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-044969","json":"https://secwatch.observer/filing/0001104659-26-044969.json","markdown":"https://secwatch.observer/filing/0001104659-26-044969.md","text":"https://secwatch.observer/filing/0001104659-26-044969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/0001104659-26-044969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/ibio-20260408x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:29:09.133549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}